Siren Biotechnology

3 articles about Siren Biotechnology

• Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)

  11/1/2023

  Siren Biotechnology announced that the California Institute for Regenerative Medicine has awarded the company a $4M translational research grant to support the development of novel AAV immuno-gene therapies for cancer.

• Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy™ for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy

  5/17/2023

  Siren Biotechnology announced the presentation of preclinical data demonstrating the effect of a novel treatment for cancer, Universal AAV Immuno-Gene Therapy, which combines AAV gene therapy and cytokine immunotherapy into a single modality.

• Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy™ for Cancer

  5/17/2023

  Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy, a revolutionary new treatment modality for cancer, launched out of stealth concurrent with its first preclinical data presentation at the ASGCT 26th Annual Meeting, taking place in Los Angeles, May 16-20th.